FILTERS

TOPICS

AUA2021 Presentation Highlights Results from a Phase 1/2 Clinical Trial of Intramural/Intravesical NanoDoce® Suspension in High-Risk Nonmuscle Invasive Bladder Cancer by CritiTech PES Partner NanOlogy

FORT WORTH (September 21, 2021) — NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that initial results from a … Continued

More >

CritiTech PES Partner Nanology Presents Additional Data at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas

FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy, LLC, a clinical-stage oncology company, announced today that additional data from its Phase 2 dose-rising and … Continued

More >

CritiTech PES Partner NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial

FT. WORTH, (April 27, 2021) — NanOlogy, LLC, a clinical-stage interventional oncology drug therapy company, announced today the first patient has … Continued

More >

CritiTech PES partner NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial

FT. WORTH, (March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been completed in its … Continued

More >

CritiTech PES partner NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®

FT. WORTH, (December 29, 2020) — NanOlogy, LLC, a clinical-stage oncology company, today announced that results from its Phase 1/2 clinical … Continued

More >